Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03993379 · ClinicalTrials.gov registry record · Phase 2
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
A Phase 2 study, sponsored by CytomX Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03993379 is a Phase 2 study that was terminated before completion, run by CytomX Therapeutics. The registered enrollment target is 3 participants.
The verdict
NCT03993379, a Phase 2 study, was terminated before completion, sponsored by CytomX Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
To obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST)
Interventions
- DRUG Ipilimumab
- DRUG CX-072
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-11-20 |
| Est. Completion | 2020-05-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03993379
The ClinicalTrials.gov registry entry for NCT03993379 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CytomX Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab is the first listed.
NCT03993379 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03993379 about?
NCT03993379 is a clinical study titled "PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors". To obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST)
What is the current status of trial NCT03993379?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2019-11-20. Estimated completion is 2020-05-21.
What interventions are being tested in trial NCT03993379?
The interventions under investigation include: Ipilimumab (DRUG), CX-072 (DRUG).
Who is sponsoring clinical trial NCT03993379?
This trial is sponsored by CytomX Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.